PENG vs FICB for Hip Fracture in ED Patients
Launched by UNIVERSITY OF VIRGINIA · Aug 15, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of regional anesthesia techniques, called the Pericapsular Nerve Group (PENG) block and the Fascia Iliaca Compartment Block (FICB), to see which one works better for managing pain in patients with hip fractures who come to the emergency department. The goal is to find out if the PENG block can provide better pain relief and reduce the risk of confusion, known as delirium, in older adults compared to the FICB.
To participate in this trial, you must be between 65 and 74 years old and have a specific type of hip fracture known as a proximal femur fracture. However, if you have certain serious health issues, are allergic to local anesthetics, or choose not to participate, you will not be eligible. If you decide to join, you can expect to receive one of the two anesthesia techniques during your treatment, and your pain levels will be monitored to help researchers understand which option is more effective. This study is currently recruiting participants, and everyone is welcome regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Proximal femur fracture
- Exclusion Criteria:
- • refusal to consent
- • hemodynamic instability
- • allergy to local anesthetics
- • severe injury with instability
- • severe medical conditions with instability
About University Of Virginia
The University of Virginia (UVA) is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on interdisciplinary collaboration, UVA leverages its extensive resources and expertise in various fields, including medicine, engineering, and public health, to drive cutting-edge studies that address pressing health challenges. The university's clinical trial programs aim to translate scientific discoveries into effective treatments, ensuring the highest standards of ethical practice and participant safety. Through its strong emphasis on community engagement and education, UVA fosters a culture of research that not only contributes to the scientific community but also enhances the well-being of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlottesville, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials